Literature DB >> 22484909

Overactivation of Ras signaling pathway in CD133+ MPNST cells.

Emma Borrego-Diaz1, Kaoru Terai, Kristina Lialyte, Amanda L Wise, Tuba Esfandyari, Fariba Behbod, Victor F Mautner, Melanie Spyra, Sarah Taylor, Luis F Parada, Meena Upadhyaya, Faris Farassati.   

Abstract

Cancer stem cells (CSCs) are believed to be the regenerative pool of cells responsible for repopulating tumors. Gaining knowledge about the signaling characteristics of CSCs is important for understanding the biology of tumors and developing novel anti-cancer therapies. We have identified a subpopulation of cells positive for CD133 (a CSC marker) from human primary malignant peripheral nerve sheath tumor (MPNST) cells which were absent in non-malignant Schwann cells. CD133 was also found to be expressed in human tissue samples and mouse MPNST cells. CD133+ cells were capable of forming spheres in non-adherent/serum-free conditions. The activation levels of Ras and its downstream effectors such as ERK, JNK, PI3K, p38K, and RalA were significantly increased in this population. Moreover, the CD133+ cells showed enhanced invasiveness which was linked to the increased expression of β-Catenin and Snail, two important proteins involved in the epithelial to mesenchymal transition, and Paxilin, a focal adhesion protein. Among other important characteristics of the CD133+ population, endoplasmic reticulum stress marker IRE1α was decreased, implying the potential sensitivity of CD133+ to the accumulation of unfolded proteins. Apoptotic indicators seemed to be unchanged in CD133+ cells when compared to the wild (unsorted) cells. Finally, in order to test the possibility of targeting CD133+ MPNST cells with Ras pathway pharmacological inhibitors, we exposed these cells to an ERK inhibitor. The wild population was more sensitive to inhibition of proliferation by this inhibitor as compared with the CD133+ cells supporting previous studies observing enhanced chemoresistance of these cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22484909     DOI: 10.1007/s11060-012-0852-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  72 in total

Review 1.  Leukaemia stem cells and the evolution of cancer-stem-cell research.

Authors:  Brian J P Huntly; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

2.  Radiation resistance and stem-like cells in brain tumors.

Authors:  Dolores Hambardzumyan; Massimo Squatrito; Massimo Squartro; Eric C Holland
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

3.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.

Authors:  T N Basu; D H Gutmann; J A Fletcher; T W Glover; F S Collins; J Downward
Journal:  Nature       Date:  1992-04-23       Impact factor: 49.962

4.  Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glycoprotein.

Authors:  D Corbeil; C A Fargeas; W B Huttner
Journal:  Biochem Biophys Res Commun       Date:  2001-07-27       Impact factor: 3.575

Review 5.  Concise review: cancer/testis antigens, stem cells, and cancer.

Authors:  Fabrício F Costa; Katarina Le Blanc; Bertha Brodin
Journal:  Stem Cells       Date:  2006-11-30       Impact factor: 6.277

Review 6.  Review paper: cancer stem cells and cancer nonstem cells: from adult stem cells or from reprogramming of differentiated somatic cells.

Authors:  J E Trosko
Journal:  Vet Pathol       Date:  2009-03       Impact factor: 2.221

Review 7.  Ras/Raf/ERK signalling and NF1.

Authors:  Marie C Harrisingh; Alison C Lloyd
Journal:  Cell Cycle       Date:  2004-10-17       Impact factor: 4.534

8.  BAX inhibitor-1 is a negative regulator of the ER stress sensor IRE1alpha.

Authors:  Fernanda Lisbona; Diego Rojas-Rivera; Peter Thielen; Sebastian Zamorano; Derrick Todd; Fabio Martinon; Alvaro Glavic; Christina Kress; Jonathan H Lin; Peter Walter; John C Reed; Laurie H Glimcher; Claudio Hetz
Journal:  Mol Cell       Date:  2009-03-27       Impact factor: 17.970

Review 9.  Cancer stem cells: a review.

Authors:  John B Spillane; Michael A Henderson
Journal:  ANZ J Surg       Date:  2007-06       Impact factor: 1.872

10.  Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase.

Authors:  J S Cox; C E Shamu; P Walter
Journal:  Cell       Date:  1993-06-18       Impact factor: 41.582

View more
  8 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

2.  Propranolol Specifically Suppresses the Viability of Tumorous Schwann Cells Derived from Plexiform Neurofibromas In Vitro.

Authors:  Ziang Zou; Linna Guo; Victor Mautner; Ralf Smeets; Lan Kiuwe; Reinhard E Friedrich
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

3.  RalA is overactivated in medulloblastoma.

Authors:  Kevin F Ginn; Ben Fangman; Kaoru Terai; Amanda Wise; Daniel Ziazadeh; Kushal Shah; Robyn Gartrell; Brandon Ricke; Kyle Kimura; Sharad Mathur; Emma Borrego-Diaz; Faris Farassati
Journal:  J Neurooncol       Date:  2016-08-26       Impact factor: 4.130

4.  Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.

Authors:  Jiang Wei; Marcus Freytag; Yvonne Schober; Wolfgang A Nockher; Victor F Mautner; Reinhard E Friedrich; Paul W Manley; Lan Kluwe; Andreas Kurtz
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

Review 5.  Ral signaling pathway in health and cancer.

Authors:  Adel Rezaei Moghadam; Elham Patrad; Elham Tafsiri; Warner Peng; Benjamin Fangman; Timothy J Pluard; Anthony Accurso; Michael Salacz; Kushal Shah; Brandon Ricke; Danse Bi; Kyle Kimura; Leland Graves; Marzieh Khajoie Najad; Roya Dolatkhah; Zohreh Sanaat; Mina Yazdi; Naeimeh Tavakolinia; Mohammad Mazani; Mojtaba Amani; Saeid Ghavami; Robyn Gartell; Colleen Reilly; Zaid Naima; Tuba Esfandyari; Faris Farassati
Journal:  Cancer Med       Date:  2017-10-18       Impact factor: 4.452

6.  CD133: a stem cell biomarker and beyond.

Authors:  Zhong Li
Journal:  Exp Hematol Oncol       Date:  2013-07-01

7.  Cancer stem cells, the ultimate targets in cancer therapy.

Authors:  Ahmed Shabbir; Tuba Esfandyari; Faris Farassati
Journal:  Onco Targets Ther       Date:  2018-01-03       Impact factor: 4.147

8.  CD133 mediates the TGF-β1-induced activation of the PI3K/ERK/P70S6K signaling pathway in gastric cancer cells.

Authors:  Youlong Zhu; Feifei Kong; Caihua Zhang; Cheng Ma; Hong Xia; Bin Quan; Huaixin Cui
Journal:  Oncol Lett       Date:  2017-10-10       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.